Gossamer Bio Inc. (GOSS) Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes Due 2027

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. SPY
3. ABBV
4. IBM
5. META
6. MU
7. ACN
8. NVDA
9. FDX
10. BLZE

Go back to Gossamer Bio Inc. (GOSS) Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes Due 2027

Gossamer Bio Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes Due 2027

May 18, 2020 4:01 PM EDT

SAN DIEGO--(BUSINESS WIRE)-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it intends to offer, subject to market and other conditions, shares of common stock and convertible senior notes due 2027 (the notes) in separate concurrent underwritten public offerings registered under the Securities Act of 1933, as amended.

Gossamer also expects to grant the underwriters of the common stock offering a 30-day option to purchase up to an additional 15% of the... More